Home  »  Companies   »  Autolus Therapeutics plc ADR (NASDAQ: AUTL)’...

Autolus Therapeutics plc ADR (NASDAQ: AUTL)’S Stock Adds 9.56%, But It May Make Sense To Invest.

Autolus Therapeutics plc ADR (NASDAQ:AUTL) price closed higher on Monday, February 12, jumping 9.56% above its previous close.

A look at the daily price movement shows that the last close reads $6.38. The company’s 5Y monthly beta was ticking 1.91. Taking into account the 52-week price action we note that the stock hit a 52-week high of $7.45 and 52-week low of $1.61. The stock subtracted -4.12% on its value in the past month.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Autolus Therapeutics plc ADR, which has a market valuation of $1.22 billion, is expected to release its quarterly earnings report Mar 05, 2024 – Mar 09, 2024.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give AUTL a short term outlook of 100% Buy on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 100% Buy.

The overview shows that AUTL’s price is at present 13.15% off the SMA20 and 21.70% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 63.53, with weekly volatility standing at 10.31%. The indicator jumps to 8.83% when calculated based on the past 30 days. Autolus Therapeutics plc ADR (NASDAQ:AUTL)’s beta value is holding at 1.91, while the average true range (ATR) indicator is currently reading 0.53.

Turning out attention to how the Autolus Therapeutics plc ADR stock has performed in comparison to its peers in the industry, here’s what we find: AUTL’s stock is 9.56% on the day and 210.67% in the past 12 months. Turning out attention to how the Autolus Therapeutics plc ADR stock has performed in comparison to its peers in the industry, here’s what we find: AUTL’s stock is 9.56% on the day and 210.67% in the past 12 months. Another comparison is with Bristol Myers Squibb Co. (BMY) whose stock price was down -0.12%% in the last trading session, and has flourished -32.01% over the past year. Also, Gilead Sciences Inc. (GILD) showed up trend of 1.06%% while its price kept floating at -14.90% over the past year.

An analysis of the Autolus Therapeutics plc ADR (NASDAQ:AUTL) stock in terms of its daily trading volume indicates that the 3-month average is 3.35. However, this figure increases on the past 10-day timeline to an average of 2.46 million.

Current records show that the company has 173.07M in outstanding shares. The insiders’ percentage holdings are 14.33% of outstanding shares while the percentage share held by institutions stands at 55.85%. The stats also highlight that short interest as of Jan 31, 2024, stood at 2.94 million shares, which puts the short ratio at the time at 2.28. From this we can glean that short interest is 1.69% of company’s current outstanding shares. Notably, we see that shares short in January rose slightly given the previous month’s figure stood at 2.16 million. But the 8.54% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.